Ribociclib with endocrine therapy (ET) is currently in clinical development for patients with early
breast cancer with hormone receptor positive (HR+)/human epidermal receptor 2 negative
(HER2-) subtype. Early breast cancer is where the disease is limited to the breast region and has
not spread to other parts of the body. Symptoms include swelling of breast regions, breast or
nipple pain, nipple retraction, change in texture of skin covering the breast, nipple discharge and
swollen lymph nodes. Despite the use of adjuvant ET, the risk of recurrence remains high in
patients with HR+ early breast cancer.
Ribociclib with endocrine therapy for HR+/HER2- early breast cancer – adjuvant treatment
Ribociclib with endocrine therapy (ET) is currently in clinical development for patients with early breast cancer with hormone receptor positive (HR+)/human epidermal receptor 2 negative (HER2-) subtype.
Indications:
Breast cancer
Therapeutic Areas:
Breast Cancer
Year:
2022